InvestSMART

Telix Pharmaceuticals Limited (ASX:TLX)

ALERT: Price-sensitive ASX Announcement for TLX
Current share price for TLX : $14.210 -0.89 (-5.89%)+
Announcement
Release
21 Jul 2026 8:26AM
Price at Release
$15.100
Full Release
download
Summary
Telix Pharmaceuticals Limited announced strong financial results for Q2 2026, reporting a revenue of US$247 million driven by a robust performance in their Precision Medicine segment. The company's strategic collaborations, notably with Regeneron, and advancements in their therapeutics and precision medicine pipelines have positioned them well for a projected FY 2026 revenue exceeding US$1 billion. Key milestones included FDA alignment on trials for their prostate cancer therapy TLX591-Tx and significant progress in their TLX250-Tx and TLX101-Tx programs. Telix also expanded their operational capabilities by opening a new facility in Melbourne and successfully issuing US$600 million in convertible bonds.
Key Points
  • Telix Pharmaceuticals reported Q2 2026 revenue of US$247 million, a 21% year-over-year increase.
  • Precision Medicine contributed US$202 million, a 30% increase year-over-year.
  • Telix expects FY 2026 revenue to exceed US$1 billion.
  • The FDA aligned on the Part 2 study of TLX591-Tx for mCRPC in the U.S.
  • Strategic collaboration with Regeneron for radiopharmaceutical therapies.
  • Research and development expenditure for FY 2026 updated to US$230 million to US$270 million.
  • First patient dosed in the LUTEON trial for TLX250-Tx.
  • Telix completed a US$600 million convertible bond issuance.
  • Opened TMS North Melbourne to enhance R&D capabilities.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.